Skip to main content

Uncomplicated Urinary Tract Infection

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Tianjin GreenPine Pharma
1 program
1
Pivmecillinam hydrochloride tabletsPhase 31 trial
Active Trials
NCT05545137Completed299Est. Feb 2024
Paratek Pharmaceuticals
1 program
Omadacycline tabletsPHASE_21 trial
Active Trials
NCT03425396Completed225Est. Jun 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Tianjin GreenPine PharmaPivmecillinam hydrochloride tablets
Paratek PharmaceuticalsOmadacycline tablets

Clinical Trials (2)

Total enrollment: 524 patients across 2 trials

NCT05545137Tianjin GreenPine PharmaPivmecillinam hydrochloride tablets

Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection

Start: Sep 2022Est. completion: Feb 2024299 patients
Phase 3Completed

Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis

Start: Jan 2018Est. completion: Jun 2019225 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.